Copy
October 22, 2019
Giving healthcare companies the exposure they deserve. Every Tuesday.
BioTuesdays by Kilmer Lucas
Share
Tweet
Share
Forward

FEATURED STORY

Salarius Pharmaceuticals targeting epigenetic causes of cancers

Salarius Pharmaceuticals (NASDAQ:SLRX) is poised to ride the growing epigenetic wave with a differentiated lead drug candidate, seclidemstat, in early clinical development for the treatment of Ewing sarcoma and advanced solid tumors.

“Seclidemstat is an oral tablet with a targeted, disease-specific mechanism of action, unlike toxic chemotherapy,” David Arthur, president and CEO, says in an interview with BioTuesdays. “Our technology targets the epigenetic causes of cancer, which is the study of the regulatory system that controls how genes are turned on or off.”

Mr. Arthur explains that in certain cancers, the proteins that regulate gene expression become dysregulated and incorrectly turn genes “on” or “off,” which in some cases, leads to cancer progression. Drugs that are able to safely modify the activity of these epigenetic regulators may correct the gene changes that are driving the disease, he suggests.

According to Mr. Arthur, epigenetics is a hot space right now, and within that space is a class of drugs called lysine-specific demethylase 1 (LSD1) inhibitors, including Salarius’ seclidemstat. 
Read the Story

SELECT BRIEFS

NASDAQ:HEPA

Hepion Pharmaceuticals

JPET publishes Hepion data highlighting CRV431’s potential to treat chronic liver diseases
 

TSXV:IGX; OTCQX:IGXT

IntelGenx

FDA accepts IntelGenx NDA resubmission for RIZAPORT

 

NASDAQ:TTNP

Titan Pharmaceuticals

To present two Probuphine posters at conference

 

TSX:ZENA

Zenabis

Cultivation output of dried cannabis up 21.8% in September

 

More Briefs


Markets


About BioTuesdays

 
BioTuesdays was created in 2009 by Kilmer Lucas, a leading healthcare-only investor relations firm. Employing a unique "outsourced in-house" partnership model, Kilmer Lucas designs and executes customized IR & PR programs for its drug development, medical device, cell therapy, diagnostics and healthcare services clients. But, most of BioTuesdays' content isn't client-driven. Rather, our mission is to give as many great healthcare companies and their stories as much exposure as we can.
Want to be featured in BioTuesdays? Get in touch with us.
Copyright © 2019 Kilmer Lucas, All rights reserved.
You are receiving this email because you signed up for the BioTuesdays newsletter.
Privacy Policy

BioTuesdays
PO Box 297
Carlisle, ON L0R 1H0 

subscribe | unsubscribe | update your preferences